Press Releases

Bronchitis Treatment Market is projected to rise at CAGR of 3.6% from 2018 to 2026

Share This Article

The bronchitis market stood at US$ 3,432.62 million in 2017 and is projected to rise at CAGR of 3.6% from 2018 to 2026.

Bronchitis Treatment Market: Contours of Evolution

Companies investing in bronchitis treatment market are interested in studying the etiology of bronchitis. Key viruses are Influenza type A and B, while key bacterial agents are Streptococcus, Mycoplasma pneumonia, and Staphylococcus. There are several risk factors when population has high disposition to develop chronic bronchitis, particularly in regions where they are exposed to high environmental pollutants. The prevalence of bronchitis is high the general population. In chronic obstructive pulmonary disease (COPD) patients, the prevalence estimates can be as high as 54%. The high burden has been highlighted as a key driver for the evolution of the bronchitis treatment market.

Get the sample copy of report@

Other key risk factors comprise tobacco smoking, increasing age, socioeconomic status, and occupational exposure. Both pharmacological and non-pharmacological interventions have gathered considerable attention among players in the bronchitis treatment market.

Key types comprise anti-inflammatory drugs, bronchodilators, and mucolytics.

A growing number of epidemiological studies has helped shed light on pharmacological interventions, spurring research on the above segments. The growing morbidity and mortality of acute and chronic bronchitis—the two types–is a key factor driving the bronchitis market.

The bronchitis market stood at US$ 3,432.62 million in 2017 and is projected to rise at CAGR of 3.6% from 2018 to 2026.

The report segments the bronchitis treatment market on the basis of region, type, drug class, and distribution channel.

bronchitis treatment market

Chronic bronchitis Segment Vie for Attention Among Researchers and Drug Makers

Among the two types, chronic bronchitis holds the leading share of the global market throughout the forecast period. The rise in the opportunities in this segment is the high morbidity and mortality rate. However, rate of developments in prognosis still seems tepid. Coordinated efforts made by all healthcare teams to improve the outcomes of pharmacological treatment for chronic is a key trend driving prospects in the bronchitis treatment market. Further, clinicians recommend making changes in lifestyle in reducing the morbidity of chronic bronchitis.

On the other hand, acute bronchitis is also garnering attention among drug makers and medical device manufacturers. The segment is expected to keep contributing significant revenues in coming years. In developed countries, given the high incidence, an array of studies have been done to understand the risk factors. These studies shed light on expected avenues in the bronchitis treatment market.

Growing Number of Clinical Trials Help Develop Novel Products

Over the years, nonpharmacological interventions have risen in popularity. The various drugs classes are antibiotics, bronchodilators, mucolytics, and, anti-inflammatory drugs. Of these, bronchodilators have been frequently recommended for the treatment of symptomatic COPD.

Advent of  novel LAMA/LABA fixed dose combination inhalers has helped in preventing the exacerbations in COPD patients. Thus, long-acting bronchodilators have attracted research targeted toward improving the mechanism. Growing number of clinical trials has helped develop long-acting bronchodilators. The findings of these studies have paved way to guidelines for reducing COPD exacerbations, thus unlocking new prospects for players in the bronchitis treatment market. Introduction of new drug regimens in COPD treatment options has expanded the horizon for stakeholders in the market. This has also led to the approval of novel LAMA/LABA fixed combinations, opening new doors to opportunities for market players.

View full report@

Research in Bronchitis Therapeutics Makes North America Key Market

The key regional markets analysed in the study comprise North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Of these, North America and Europe accounted for the major share of the global bronchitis treatment market in 2017. These regional markets have been fuelled by incessant research in bronchitis therapeutics to reduce the morbidity of the disease.

On the other hand, Asia Pacific is expected to be expand at remarkably high CAGR during 2018 – 2026. Several economies are witnessing marked progress in healthcare infrastructures to meet the demand for rising various patient populations. In particular, a robust impetus to the growth of the Asia Pacific bronchitis market comes from growing demand from elderly populations. In the cohort, smoking has been a key risk factor, in the light of other respiratory problems they may be facing. Further, the regional market has seen new avenues for growth due to extensive research and development done to reduce the morbidity of chronic bronchitis due to pollutants. High presence of pollutants in numerous developing economies in Asia has bolstered these research.

Growing Awareness of COPD and High Morbidity of Bronchitis Fuels Asia Pacific Market

Growing awareness of COPD in general population in developing economies is also a favorable trend in the expansion of potential opportunities in the bronchitis treatment market. On the other hand, there has been widespread efforts by governments in several of these nations to make public aware of the risk factors associated with cigarette smoking. Pharmaceutical companies have in recent years have come out with new non-pharmacological interventions, and the electronic media has been promoting the effectiveness of such treatments.

Asia Pacific is thus has large latent opportunities for developers of bronchodilators. The regional market is expected to clock CAGR of 4.0% from 2018 to 2026.

Purchase Complete Report Now@

Companies extensively profiled in the report on the bronchitis treatment market are Boehringer Ingelheim International GmbH., Sanofi Aventis, Melinta Therapeutics, Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline plc, Novartis AG, and AstraZeneca.

The global bronchitis treatment market has been segmented as given below:


  • Acute Bronchitis
  • Chronic Bronchitis

Drug Class

  • Antibiotics
  • Anti-inflammatory Drugs
  • Bronchodilators
  • Mucolytics

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies


  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • U.K.
  • Italy
  • France
  • Spain
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • Japan
  • Australia & New Zealand
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa


1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights

2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology

3. Executive Summary
3.1. Global Bronchitis Treatment Market: Market Snapshot

4. Market Overview
4.1. Global Bronchitis Treatment Market: Type Overview
4.2. Global Bronchitis Treatment Market: Key Industry Developments
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Bronchitis Treatment Market Revenue Projections, 2016–2026
4.5. Porter’s Five Forces Analysis
4.6. Global Bronchitis Treatment Market Outlook

5. Market Outlook
5.1. Pipeline Analysis
5.2. Key Market Trends
5.3. Disease Epidemiology

6. Global Bronchitis Treatment Market Analysis, by Type
6.1. Key Findings
6.2. Introduction
6.3. Global Bronchitis Treatment Market Value Share and Attractiveness Analysis, by Type
6.4. Global Bronchitis Treatment Market Value Forecast, by Type
6.4.1. Acute Bronchitis
6.4.2. Chronic Bronchitis
6.5. Global Bronchitis Treatment Market Analysis, by Type

7. Global Bronchitis Treatment Market Analysis and Forecast, by Drug Class
7.1. Key Findings
7.2. Introduction
7.3. Global Bronchitis Treatment Market Value Share and Attractiveness Analysis, by Drug Class
7.4. Global Bronchitis Treatment Market Value Forecast, by Drug Class
7.4.1. Antibiotics
7.4.2. Anti-inflammatory Drugs
7.4.3. Bronchodilators
7.4.4. Mucolytics
7.5. Global Bronchitis Treatment Market Analysis, by Drug Class

8. Global Bronchitis Treatment Market Analysis, by Distribution Channel
8.1. Key Findings
8.2. Introduction
8.3. Global Bronchitis Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
8.4. Global Bronchitis Treatment Market Value Forecast, by Distribution Channel
8.4.1. Hospital Pharmacies
8.4.2. Retail Pharmacies
8.4.3. Online Pharmacies
8.5. Global Bronchitis Treatment Market Analysis, by Distribution Channel

9. Global Bronchitis Treatment Market Analysis, by Region
9.1. Global Bronchitis Treatment Market Scenario, by Country
9.2. Global Bronchitis Treatment Market Value Share and Attractiveness Analysis, by Region
9.3. Global Bronchitis Treatment Market Value Forecast, by Region
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific
9.3.4. Latin America
9.3.5. Middle East & Africa

10. North America Bronchitis Treatment Market Analysis


Purchase Complete Report Now@

You can place an order or ask any questions, please feel free to contact | +1 9197 992 333

About Us

QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).

QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.

For Latest Update Follow Us:

Related Articles

Back to top button